All In Biotech

Drug Trial Radar · NCT05361382

Head-to-Head Harmonization of Tau Tracers in Alzheimer's Disease

Longitudinal Multicenter Head-to-Head Harmonization of Tau PET Tracers

Last checked: Nov 20, 2026Latest source record: Sep 8, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

822

Actual

Start

Mar 2, 2022

Primary completion

May 31, 2027

Study completion May 31, 2027

Sponsor

Lead sponsor
Tharick PascoalAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
National Institute on Aging (NIA)
First posted
May 4, 2022

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 90 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to compare/harmonize cross-sectional and longitudinal tau tangle measurements obtained with the tau PET radiopharmaceuticals Flortaucipir and MK-6240 to elucidate the advantages and caveats of their use in clinical trials/practice and provide parameters to integrate their estimates.

Conditions

  • Alzheimer Disease

Interventions

  • 18F-Flortaucipir radiopharmaceuticalDrug

    Flortaucipir is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 10 millicuries of the radiopharmaceutical.

  • 18F-MK-6240 radiopharmaceuticalDrug

    MK-6240 is a PET radiopharmaceutical that binds to tau neurofibrillary tangles. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the radiopharmaceutical.

  • Amyloid-β radiopharmaceutical (11C-PiB or 18F-Florbetaben or 18F-NAV-4694 or 18F-Flutemetamol)Drug

    The clinical sites will use either PiB, Florbetaben, Flutemetamol, or NAV-4694 as the amyloid-β PET radiopharmaceutical. The amyloid-β PET radiopharmaceutical binds to amyloid-β plaques. Participants will receive a bolus intravenous injection of approximately 15 millicuries of the PiB radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 8 millicuries of the Florbetaben or NAV-4694 radiopharmaceutical. Participants will receive a bolus intravenous injection of approximately 5 millicuries of the Flutemetamol radiopharmaceutical.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cross-sectional tau PET uptake valuesTime frame: 2 years from enrollment
  2. Longitudinal change in tau PET uptake values over 18 monthsTime frame: 5 years from enrollment

Locations

9 sites in 3 countries. Site status is shown where the registry gives one.

  • Lawrence Berkeley National Laboratory

    Berkeley, California

  • University of California San Francisco

    San Francisco, California

  • Mayo Clinic

    Rochester, Minnesota

  • Washington University in St. Louis

    St Louis, Missouri

  • University of Pittsburgh

    Pittsburgh, Pennsylvania

  • Brown University

    Providence, Rhode Island

  • Houston Methodist Neurological Institute

    Houston, Texas

  • McGill University

    Montreal, Quebec, Canada

  • Sant Pau Biomedical Research Institute

    Barcelona, Spain, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.